MEDICA 2026|Microprofit Biotech Successfully Concludes Four Inspiring Days in Düsseldorf

Microprofit Biotech Successfully Concludes MEDICA 2026 in Düsseldorf

Düsseldorf, Germany — MEDICA 2026 has successfully concluded after four inspiring days of global healthcare exchange. During the exhibition, Shenzhen Microprofit Biotech Co., Ltd.(Microprofit Biotech) welcomed long-time partners, new customers, distributors, and industry professionals at Hall 3 | Booth 3A16.

合照-官网

As one of the important international platforms for the medical and healthcare industry, MEDICA brought together companies and professionals from around the world to explore new technologies, market trends, and cooperation opportunities. For Microprofit Biotech, the exhibition provided a valuable opportunity to connect face to face with global partners and present its latest developments in in vitro diagnostics, rapid test solutions, and healthcare-related products.


Showcasing Respiratory Infection Rapid Test Products

At MEDICA 2026, Microprofit Biotech highlighted its latest respiratory infection rapid test products, designed to support timely and efficient testing in diverse healthcare settings.


Respiratory infection testing continues to play an important role in clinical diagnosis, primary care, and public health management. By focusing on rapid, convenient, and reliable testing solutions, Microprofit Biotech aims to provide global customers with practical options for improving diagnostic efficiency and supporting timely clinical decision-making.


Presenting Immunofluorescence POCT Quantitative Testing

Microprofit Biotech also presented its capabilities in immunofluorescence POCT quantitative testing, demonstrating the company’s continued focus on point-of-care testing and multi-scenario diagnostic applications.


With growing demand for faster and more accessible testing, immunofluorescence POCT quantitative testing offers flexible possibilities for healthcare institutions, laboratories, and decentralized testing environments. Microprofit Biotech continues to strengthen its product portfolio to meet the evolving needs of global markets.


POST1-官网.png


Introducing AI Pathogen Recognition System

Another key highlight at the exhibition was the AI pathogen recognition system.


As artificial intelligence becomes increasingly integrated into medical testing, AI-assisted recognition may help improve testing efficiency, support standardized interpretation, and enhance user experience. Microprofit Biotech’s exploration of intelligent diagnostic technologies reflects its ongoing commitment to innovation and product development.


Expanding Product Display with Raw Materials and Skincare Products

In addition to IVD and rapid test products, Microprofit Biotech also showcased raw materials and skincare products during MEDICA 2026, presenting a broader view of its product development and cooperation opportunities.


Throughout the four-day exhibition, the Microprofit Biotech team held in-depth discussions with customers and partners from different markets, exchanging insights on product applications, market demand, channel cooperation, and future collaboration.


POST2-官网.png


Moving Forward with Global Partners

Microprofit Biotech sincerely thanks all partners, customers, and friends who visited the booth during MEDICA 2026. Every conversation, meeting, and exchange of ideas was valuable and inspiring.


Although MEDICA 2026 has come to an end, Microprofit Biotech’s global journey continues. The company will keep focusing on IVD innovation, rapid test solutions, and international cooperation, providing reliable products and services for global healthcare markets.


Next stop: WHX Dubai 2027.

Microprofit Biotech looks forward to meeting you again in Dubai.

微信图片_20261120093842_1001_1064.jpg


86-18929376151

Skin care
Microprofit